A Phase 4 interventional study of CTM Boost and PRP in Tendinopathy, Shoulder Pain and Rotator Cuff Tendinitis, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute). Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Tendinopathy with a site in United States — 15 open to participants now, 17 under way, none of them phase 3. Tendinopathy · United States.
Among the 99 studies in Tendinopathy with a site in United States, this one is the 22nd largest by enrollment of the 89 interventional ones that give a count, is one of 10 that started in 2023, is one of 15 in phase 4, reaches primary completion later than 4 of the 16 other live ones, and was the 83rd registered.
399 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.
Browse Tendinopathy studies →15 of the 99 studies in Tendinopathy with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 18–80
Joint & Vascular Institute · Sites in United States
Ages 25–80
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 18+
University of Utah · Sites in United States
Ages 18+ · Healthy volunteers
Brigham and Women's Hospital · Sites in United States
Ages 21–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 46 Tendinopathy studies recruiting now, 17 (37%) set no upper age limit and 22 (48%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 8 · Phase 4 15
First in 2002; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 92 is above the median of 48 across 333 interventional studies indexed under Tendinopathy.
Median enrollment 40 across the 89 interventional studies, 66 across the 10 observational. Of the 68 that completed or were terminated, 25 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 99 have an industry lead sponsor. The 10 most frequent:
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) is the lead sponsor of 49 studies on the registry; 20 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) has 2 studies filed under Tendinopathy — fewer than ten, so there is no comparison to draw.
8 of the studies in Tendinopathy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06160427Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)Connective Tissue Matrix for Rotator Cuff Tendinopathy | 2027-01-15 |
| NCT06095050Brigham and Women's HospitalEmbolization Treatment of Chronic Refractory Shoulder Tendinopathy | 2027-01-16 |
| NCT07642583Brooke Army Medical CenterDry Needling and Exercise for Mid-portion Achilles Tendinopathy | 2027-03-30 |
| NCT07553273The University of Texas Medical Branch, GalvestonVibratory Anesthesia on Pain Following Corticosteroid Injections | 2027-04 |
| NCT02600910The University of Texas Medical Branch, GalvestonNatural History of Shoulder Pathology in Manual Wheelchair Users | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 99 studies in Tendinopathy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to determine if the effectiveness of a single injection of CTM Boost in the treatment of patients with rotator cuff tendinopathy (RCT) is as effective as a single injection of platelet rich plasma (PRP) in reducing the symptoms of RCT.
Rotator cuff tendinopathy (RCT), is a chronic degenerative process which causes both shoulder pain as well as limited range of motion. It is currently estimated that approximately 5% of RCT is being managed surgically, which highlights the importance of effective non-operative treatment strategies.
The advent of platelet rich plasma (PRP), a sample of blood drawn from a patient and concentrated to include mainly platelets and potent inflammatory mediators which promote healing, has shown promise as another treatment modality when injected at the site of tendon damage. Placenta-derived decellularized connective tissue matrix (CTM) may represent an alternative therapy for RCT. Placenta-derived biologics can be administered as an injection and have been shown to promote tenocyte proliferation and to reduce inflammation in vitro, thus potentially accelerating and enhancing tendon healing.
This study is being conducted to determine if injection of CTM Boost is non-inferior to injection of PRP with regard to pain and function at Month 6 post-injection in patients with rotator cuff tendinopathy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2.0 cc (cubic centimeter) dose injection of CTM Boost will be administered by injection directly into the rotator cuff using a 20 gauge needle.
Biological: CTM Boost
Each participant randomized to this arm will receive a single injection of Platelet Rich Plasma (PRP).
Biological: PRP
Connective Tissue Matrix (CTM) Boost is a decellularized Human Cellular and Tissue Based Allograft derived from placental connective tissue. It is considered a minimally-manipulated biologic by the FDA and is marketed as an allograft for repairing connective tissue. It is administered via injection.
PRP is derived by a sample of blood drawn from a patient and concentrated to include mainly platelets and potent inflammatory mediators which promote healing. At baseline, a blood draw of 60 milliliter (mL) will be obtained and concentrated in an Angel System to yield 5 cc of PRP and a supra-physiological concentration of white blood cells. All injections will be done under ultrasound guidance. A two-part injection process will be used. An advancing 20 gauge 1.5-inch needle first placed 3 mL of 1% xylocaine proximal to the tendinopathic area or tear. The needle will then be re-inserted at the proximal aspect of the lesion and slowly removed while infiltrating of 5 mL of PRP without activation with Calcium Chloride/thrombin at the lesion and surrounding tendon.
determine if injection of CTM Boost is non-inferior to injection of PRP
Mean Western Ontario Rotator Cuff Index (WORC) Score The WORC has 21 items in four domains, including physical symptoms (10 questions), sports/recreation/work (4 questions), lifestyle (4 questions) and emotions (3 questions). Raw scores range from 0 to 2100, with a higher score indicating decreased quality of life because of pathological condition of the rotator cuff.
Time frame: 6 months
Mean Western Ontario Rotator Cuff Index (WORC) Score
Mean Western Ontario Rotator Cuff Index (WORC) Score The WORC has 21 items in four domains, including physical symptoms (10 questions), sports/recreation/work (4 questions), lifestyle (4 questions) and emotions (3 questions). Raw scores range from 0 to 2100, with a higher score indicating decreased quality of life because of pathological condition of the rotator cuff.
Time frame: at 6 months
assessment of superiority of CTM to PRP (if non-inferiority established)/ WORC Score
Mean Western Ontario Rotator Cuff Index (WORC) Score The WORC has 21 items in four domains, including physical symptoms (10 questions), sports/recreation/work (4 questions), lifestyle (4 questions) and emotions (3 questions). Raw scores range from 0 to 2100, with a higher score indicating decreased quality of life because of pathological condition of the rotator cuff.
Time frame: Each visit up to 24 months
assessment of superiority of CTM to PRP (if non-inferiority established) / VAS Pain Scale
Visual Analog Scale (VAS) pain scale The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').
Time frame: Each visit up to 24 months
assessment of superiority of CTM to PRP (if non-inferiority established) / SANE
Single Assessment Numeric Evaluation (SANE) The Single Assessment Numeric Evaluation (SANE) is a patient rating from 0-100. Patients rate their current illness score in relation to their pre-injury baseline. SANE scores are most commonly used by orthopedic sports specialist surgeons, and usually for the shoulder and the knee.
Time frame: Each visit up to 24 months
assessment of superiority of CTM to PRP (if non-inferiority established) / ASES
American Shoulder and Elbow Surgeons Shoulder (ASES) Score The ASES score is a 10-item measure of shoulder pain and function. Pain is assessed on a 10-cm visual analog scale (VAS) and accounts for 50% of the total score. The remaining 50% of the score is determined by the responses to 10 4-point Likert-scale questions related to physical function
Time frame: Each visit up to 24 months
assessment of superiority of CTM to PRP (if non-inferiority established) / empty can exercise
empty can exercise with dumbbell resistance (number of seconds to fatigue)
Time frame: Each visit up to 24 months
assessment of superiority of CTM to PRP (if non-inferiority established) / side laying external rotation with dumbbell resistance
Side-lying external rotation with dumbbell resistance (number of repetitions in 30 seconds)
Time frame: Each visit up to 24 months
assessment of superiority of CTM to PRP (if non-inferiority established) / full can with dumbbell resistance
Full can exercise with dumbbell resistance (number of repetitions in 60 seconds)
Time frame: Each visit up to 24 months
assessment of superiority of CTM to PRP (if non-inferiority established) / external rotation at 0 and 90 degrees
External rotation at 0 and 90 degrees with Thera-Band resistance (number of seconds to fatigue)
Time frame: Each visit up to 24 months
safety of injection of CTM boost compared to PRP
number of adverse events
Time frame: 6 months
severity of tendinopathy
Magnetic Resonance Imaging (MRI)-based grading scale MRIs will be scored on rubric from 0-5: 0, no tendinopathy; 1, mild tendinopathy; 2, moderate tendinopathy; 3, moderate tendinopathy + partial thickness tear present; 4, severe tendinopathy +partial thickness tear present; 5, severe tendinopathy + full thickness tear present
Time frame: 6 months
assessment of superiority of CTM to PRP (if non-inferiority established)
serum levels of inflammatory cytokines IL-1β and TNF-α as well as serum level of Fibroblast growth factor (FGF)
Time frame: 6 months
Plan to share: No
Started Dec 2023 (actual). Primary completion is estimated for Jan 2027, 37 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)